MEDICAMEN BIOTECH
|
|
BOM : 531146     NSE : MEDICAMEQ     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Sep 25,2023 |
Price(EOD): βΉ 658.85
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: βΉ 836.74 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
MEDICAMEN BIOTECH | -3.2% | -9.4% | -41.7% |
SUN PHARMACEUTICAL INDUSTRIES | -2.1% | 0.6% | 23.6% |
DIVIS LABORATORIES | -1.4% | 2% | 2% |
CIPLA | -5% | -3.3% | 8.7% |
DR REDDYS LABORATORIES | -5% | -7.9% | 30.8% |
TORRENT PHARMACEUTICALS | -2% | -5.8% | 22.5% |
ABBOTT INDIA | -2.8% | -2.2% | 24.5% |
ZYDUS LIFESCIENCES | -6.4% | -6% | 60.7% |
ALKEM LABORATORIES | -2.9% | -4.3% | 6.8% |
FUNDAMENTAL ANALYSIS OF MEDICAMEN BIOTECH
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF MEDICAMEN BIOTECH
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
55.24
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 15.09 Cr
[Latest Qtr - Jun2023 - Consolidated Results ] 4.31
P/B Calculated based on Book Value of Rs 193.29 Cr
[Latest Year - Mar2023 - Consolidated Results ] 5.57
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 149.72 Cr
[Latest Qtr - Jun2023 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
384% 2540% 2540% |
SHARE PRICE MOMENTUM OF MEDICAMEN BIOTECH
MEDICAMEN BIOTECH vs SENSEX
DEBT OF MEDICAMEN BIOTECH
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2022 2021 2020 Avg_3yrs |
0.18 0.15 0.1 0.14 |
0.19 0.15 0.1 0.15 |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF MEDICAMEN BIOTECH
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Jun2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF MEDICAMEN BIOTECH
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
8.48% 7.1% 7.48% 4.7% |
26.76% 22.87% 8.25% 10.04% |
QtrlyTrend |
8 | |
Latest Qtr: Jun2023 | ||
Quarterly Result Analysis → |
MEDICAMEN BIOTECH related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE MIDSMALLCAP | -1.6% | 3.3% | 26.5% |
S&P BSE SMALL CAP | -1.9% | 2.9% | 27.3% |
S&P BSE ALLCAP | -2.2% | 1.9% | 13.3% |
S&P BSE HEALTHCARE | -3.1% | -1.1% | 22.6% |
You may also like the below Video Courses
FAQ about MEDICAMEN BIOTECH
Is MEDICAMEN BIOTECH good for long term investment?
As on Sep 25,2023, the Fundamentals of MEDICAMEN BIOTECH look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of MEDICAMEN BIOTECH . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is MEDICAMEN BIOTECH UnderValued or OverValued?
As on Sep 25,2023, MEDICAMEN BIOTECH is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of MEDICAMEN BIOTECH ?
As on Sep 25,2023, the Intrinsic Value of MEDICAMEN BIOTECH is Rs. 24.96 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 136.26
Fair Value [Median EV / Sales Model] : Rs. 24.96
Fair Value [Median Price / Sales Model] : Rs. 24.96
Estimated Median Fair Value of MEDICAMEN BIOTECH : Rs. 24.96
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.
Is MEDICAMEN BIOTECH trading at a Premium or Discount?
As on Sep 25,2023, MEDICAMEN BIOTECH is trading at a Premium of 2539% based on the estimates of Median Intrinsic Value!